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Late cardiomyopathy in childhood acute myeloid
leukemia survivors: a study from the L.E.A. program
Prognosis of pediatric acute myeloid leukemia (AML) has
improved significantly over the past two decades with sur-
vival rates now approaching 70%.1 Therapy consists of a
limited number of intensive chemotherapy courses mainly
based on cytarabine and anthracycline.2,3 Many pediatric
late anthracycline cardiotoxicity studies have concerned
heterogeneous diagnostic groups. Moreover, single child-
hood cancer studies were mainly conducted in acute lym-
phoblastic leukemia, whereas the highest doses of anthra-
cycline are given in children with AML.4-6 We report here a
prospective multi-centric study of late cardiotoxicity in 185
patients surviving childhood AML. All were treated after
1989 in French clinical trials using intensive chemotherapy
alone or chemotherapy and allogeneic hematopoietic stem
cell transplantation (HSCT).
L.E.A. (Leucémie Enfant & Adolescent) is a French
prospective long-term follow-up program involving all
childhood acute leukemia survivors treated in the partici-
pating centers since 1980. Details of the programm are pro-
vided elsewhere.7 As of 31 December 2011, 282 childhood
AML survivors fulfilled the L.E.A. inclusion criteria and 218
(77.3%) of them agreed to participate. Among these 218,
185 were treated according to one of the 6 multicenter trial
protocols ongoing in France after January 1989. All 185 had
serial echocardiographic examination as part of their L.E.A.
program, and all were included in the present study. All
provided written informed consent. Cardiotoxicity was
defined by either clinical symptoms of congestive heart fail-
ure or by an abnormal echocardiographic left ventricular
function. Left ventricular function was considered abnor-
mal when the shortening fraction (SF) was less than 28%
or when the left ventricular ejection fraction (LVEF) was
less than 55% on 2D echocardiography.8-10 Cardiotoxicity
was classified as late when it started or persisted beyond
one year after the completion of first-line treatment.9
Cumulative anthracycline doses used in each trial are
described in the Online Supplementary Table S1, as well as
the doxorubicin-equivalent doses using conversion factors
of 0.83, 4.0 and 5.0 for daunorubicin, mitoxantrone and
idarubicin, respectively.10,11 Assessment of health status,
long-term late effects on health-related quality of life (QoL),
and statistical analysis are described in the Online
Supplementary Appendix.
Characteristics of the study cohort are summarized in
Table 1. Median age at the time of AML diagnosis and
median follow-up duration to last cardiac evaluation were
6.53 and 9.5 years, respectively. Thirty-seven patients had
a history of relapse. Median cumulative anthracycline dose
was 372 mg/m² (Online Supplementary Figure S1). Ninety-
nine patients were treated by chemotherapy alone, where-
as the other 86 patients also received HSCT (57 in first
remission, 25 in second remission, and 4 in more advanced
disease). Thirty children received total body irradiation
(TBI), but only 10 among the 57 transplanted in first remis-
sion did so. 
Median number of echographic evaluations was 3 per
patient. Subclinical cardiotoxicity (SCC) was observed in 23
of 185 patients (12.4%) at least once during their follow-up
program. Median time from AML diagnosis to SCC detec-
tion was 4.40 years. In these 23 patients, the median value
of the worst SF was 27% and the median value of the
worst LVEF was 52. Only 3 of 23 patients had a worse SF
value of less than 25% (2 had 20%; 1 had 24%). Six of 23
received anti-congestive therapy and none had cardiac
transplantation. Five of those receiving anti-congestive
therapy were still being treated at time of last evaluation,
and 4 had more than 28% SF and more than 55% LVEF.
Seventeen patients never received treatment: 11 had spon-
taneous improvement with more than 28% SF and more
than 55% LVEF at last evaluation. Finally, at last cardiac
evaluation, only 8 patients had an abnormal left ventricular
function. Cumulative incidence (CI) of cardiotoxicity, esti-
mated by the Kaplan-Meier method was 16% and 27% at
10 and 15 years, respectively (Figure 1A). CI of anti-conges-
tive treatment at the same follow-up times was 5% and
7%.
The risk of developing cardiotoxicity depended on a pre-
vious history of relapse and on the cumulative anthracy-
cline dose. At ten years from diagnosis, CI was 35% versus
11% in patients with or without history of relapse (P=0.02)
(Figure 1B). Among 148 patients without any history of
relapse, 10-year CI of cardiotoxicity was 14% in 97 patients
treated with chemotherapy alone versus 8% in 51 patients
who underwent HSCT in first remission (NS, Figure 1C). In
transplanted children, the risk was not modified by either a
grade 2-4 acute or an extensive chronic graft-versus-host
disease. The CI of anti-congestive treatment in these 148
patients who never experienced relapse was 3% at ten and
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Table 1. Patients characteristics.
                                                                                N=185
Age at diagnosis (median,   IQR)                           6.53  (2.53 - 11.87)
0 - 2.53                                                                                  46  (24.9%)
2.53 - 0.6.53                                                                          47  (25.4%)
6.53 - 11.87                                                                           46 (24.9%)
≥11.87                                                                                  46  (24.9%)
Sex                                                                                                  
Male                                                                                     91  (50.8%)
Female                                                                                 94  (49.2%)
First-line therapy                                                                        
LAM 89/91                                                                            54  (29.2%)
ELAM02                                                                               98  (52.9%)
EORTC 58872 - 58921                                                        24  (13.0%)
APL 2000 + 1993                                                                   9  (4.9%)
Cumulative anthracycline dose (mg/m2)                               
≤460 mg/m²                                                                        170  (91.9%)
>460 mg/m²                                                                          15  (8.1%)
History of relapse                                                                       
Yes                                                                                         37  (20%)
no                                                                                          148  (80%)
Allogeneic HSCT                                                                          
All  patients                                                                        86  (46.5%)
HSCT in CR1                                                                       57  (30.8%)
Conditioning with total body irradiation                     30  (34.9%)
Children who received more 
than one HSCT [n (%)]                                                     7  (3.7%)
Type of graft                                                                                  
HLA-identical sibling donor                                            46  (54.1%)
HLA-haploidentical related donor                                  5  (5.9%)
Unrelated donor                                                               20  (22.4%)
Unrelated cord blood                                                      15  (17.6%)
Median follow-up duration                                      9.50  (5.12 - 14.42)
from diagnosis to last echocardiogram
(years, IQR)                                                                                 
Median number of echocardiogramm  (IQR)              3  (2 - 5)
IRQ: interquartile; HSCT: allogeneic hematopoietic stem cell transplantation.
15 years. The value of 460 mg/m² was identified as a
threshold of cumulative dose of anthracycline with receiver
operating characteristics (ROC) curve, with a sensitivity of
26.09%, a specificity of 94.44%, and an accuracy of
85.95%. The 10-year SCC estimated risk was 37% in
patients treated with more than 460 mg/m² and 15% in
patients with less (P=0.02). History of relapse and a higher
cumulative anthracycline dose were the only risk factors
that proved significant in the univariate analysis (Online
Supplementary Table S2). Both factors remained significant
in the multivariate Cox regression analysis after including
the following potential confounding variables: sex, age at
AML diagnosis, HSCT in first complete remission and TBI
(Tables 2 and 3). When distributing patients according to
the cumulative number of long-term late effects, patients
with SCC were significantly more severely impaired:
43.5% of them developed more than 2 other sequelae ver-
sus 13.8% of patients without SCC (Online Supplementary
Figure S2). The mean number of late effects, excluding car-
diac dysfunction, was 2.22+-0.29 in the first group versus
1.43+-0.09 in the second group (P=0.004). Among 73
patients who had reached adulthood at time of evaluation,
15 had subclinical cardiotoxicity and 58 did not. We did not
detect any difference in the self-reported QoL between the
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Table 2. Risk factors for the occurrence of subclinical cardiotoxicity.
Multivariate Cox model including history of relapse.
                                                     Hazard ratio                       P
                                                     HR (IC 95%)                        
Sex                                                                                                             
Females                                             Reference values                        
Males                                                   0.60  (0.24 - 1.5)                     0.282
Age at diagnosis 
(distribution by quartile)                                                                     
0 - 2.53                                                             ref                                      
2.53 - 6.53                                           1.24  (0.40 - 3.75)                    0.709
6.53 - 11.83                                         1.01  (0.29 - 3.44)                    0.991
≥11.83                                                 1.01  (0.27 - 3.79)                    0.983
Relapse                                                                                                     
No                                                        Reference values                        
Yes                                                      4.26  (1.42 - 12.79)                   0.010
HSCT in 1st CR                                                                                          
No                                                                                                                
Yes                                                       1.54  (0.55 - 4.31)                    0.412
TBI                                                                                                              
No                                                        Reference values                        
Yes                                                       0.90  (0.28 - 2.84)                    0.856
A
B
C
Figure 1. Cumulative incidence subclinical cardiotoxicity over time
based on Kaplan-Meier estimates (A), for all patients (n=185); (B)
for patients with (red line) or without (blue line)  history of relapse
(C) among 148 patients without history of relapse, cumulative inci-
dence of SCC in 97 patients treated with chemotherapy alone (blue
line) versus 51 patients with chemotherapy and HSCT (red line).
Table 3. Risk factors for the occurrence of subclinical cardiotoxicity.
Cox model including cumulative anthracycline dose.
                                                     Hazard Ratio                      P
                                                     HR (IC 95%)                        
Sex                                                                                                             
Females                                             Reference values                        
Males                                                  0.72  (0.28 - 1.80)                    0.475
Age at diagnosis 
(distribution by quartile)                                                                     
0 - 2.53                                               Reference values                        
2.53 - 6.53                                           1.22  (0.40 - 3.72)                    0.733
6.53 - 11.83                                         0.79  (0.23 - 2.69)                    0.704
≥11.83                                                 0.88  (0.24 - 3.22)                    0.843
Cumulative anthracycline dose  
(mg/m² equ doxo)                                                                                  
<460                                                    Reference values                        
≥460                                                   3.42  (1.10 - 10.72)                   0.035
HSCT in 1st CR                                                                                        
No                                                                                                                
Yes                                                       1.03  (0.38 - 2.80)                    0.950
TBI                                                                                                              
No                                                        Reference values                        
Yes                                                       1.39  (0.45 - 4.26)                     0.57
TBI: total body irradiation; HSCT: allogeneic hematopoietic stem cell 
transplantation; CR: complete response.
two groups (Online Supplementary Table S3).
Online Supplementary Table S4 provides details on the
main late cardiotoxicity studies previously conducted in
childhood AML survivors. In our study, overall prevalence
of late cardiotoxicity was 12.4% resulting in a 16% 10-year
CI. Furthermore, the risk was strongly dependent on the
total amount of therapy: 10-year CI was 11% in patients
who received first-line therapy alone compared to 35% in
those who also required salvage therapy for relapsed dis-
ease. The same feature has already been published by
Temming et al. who reported a 12% prevalence of late car-
diotoxicity after first-line treatment only versus 37% after
first-line treatment plus salvage therapy for relapse.12 The
German group also underlined a high risk of late cardiotox-
icity in patients who had been treated twice with anthracy-
cline because of secondary AML, which is consistent with
our results.13 In transplanted children, when our study was
restricted to patients who never experienced leukemia
relapse, we did not detect any difference in late cardiotox-
icity between those who received HSCT during their first
CR and those treated with chemotherapy only. Similar
results have been published by Leung et al.14 Most of the
children transplanted for AML in France since 1989
received busulfan and cyclophosphamide as conditioning
regimen.15 Although a young age at diagnosis had been
identified as a risk factor for cardiotoxicity in previous pub-
lications,9 this was not observed in our study, perhaps part-
ly because in French AML trials the anthracycline dose was
deceased in infants under one year of age. We also
acknowledge that the statistical power of a risk factor
analysis is limited by the relatively low number and mild
severity of cardiotoxic events. 
Because L.E.A. is a prospective cohort with serial health
status evaluations, we were able to provide follow-up data
after diagnosis of cardiomyopathy. Interestingly, only 6
among 23 patients with late cardiotoxicity required anti-
congestive therapy. Fifteen among these 23 (including 4 of
6 who received therapy) had improvement and, at last
L.E.A. evaluation, no longer met our echographic criteria
for cardiomyopathy. This feature of transient cardiomyopa-
thy occurrence has already been reported in the German as
well as in the UK experience of childhood AML survivors’
late cardiotoxicity.12,13 Although potentially reassuring, this
concept of possible improvement must be interpreted with
caution because long-term persistence of such an improve-
ment cannot be predicted and will require longer follow up.
In addition, we cannot exclude the possibility that some
apparent improvements were, in fact, due to underestima-
tion of cardiac function in a previous echocardiogram.
Impairment in several domains of QoL has been
described in childhood cancer survivors, but to the best of
our knowledge, our study is the first to focus on the impact
of late cardiac dysfunction. It is worthy of note that we did
not detect any difference in QoL domains when comparing
patients with or without late cardiac toxicity. This could
appear surprising, but we have to consider that the QoL
questionnaire assesses patients’ self-perceived health sta-
tus. None of the patients with echocardiographic abnor-
mality suffered from clinical heart failure and only a few
required anti-congestive therapy. Moreover, more than half
of patients detected with SCC had further improvement
and normal cardiac function at last evaluation, which is
when they filled in the QoL questionnaire. 
Finally, the relatively low burden of cardiac complica-
tions described here should be interpreted in the context of
a late complication whose prevalence and severity increase
according to the length of post-therapy interval.9 Thus,
although the median follow-up time between diagnosis
and last evaluation was 9.5 years in this L.E.A study, an
even longer follow-up duration is required. 
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